Heparan sulfate proteoglycans in experimental models of diabetes: A role for perlecan in diabetes complications

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 6, 2001, Pages 412-421

  Conde Knape, Karin ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Animal models; Diabetes; HSPG; Lipoproteins; Perlecan

Indexed keywords

AMYLIN; CARBOHYDRATE; CELL PROTEIN; CORE PROTEIN; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; PERLECAN; PROTEOGLYCAN; PROTEOHEPARAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; PROTEINURIA; RAT; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; BASEMENT MEMBRANE; CORONARY DISEASE; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; ISLETS OF LANGERHANS; MICE; RATS;

EID: 0035663766     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.236     Document Type: Review

References (114)

1. Matrix proteoglycans: From molecular design to cellular function
2. Functions of cell surface heparan sulfate proteoglycans
3. Perlecan is essential for cartilage and cephalic development
4. Life without perlecan has its problems
5. Perlecan maintains the integrity of cartilage and some basement membranes
6. The degradations of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases
7. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor 7
8. Perlecan heparan sulfate proteoglycan: A novel receptor that mediates a distinct pathway for ligand catabolism
9. Visualization of the large heparan sulfate proteoglycan from basement membrane
10. Isolation of a heparan-sulfate-containing proteoglycans from basement membrane
11. Structural and functional characterization of the human perlecan gene promoter
12. Structural characterization of the complete human perlecan gene and its promoter
13. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein receptor, and the neural cell adhesion molecule
14. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan
15. An LRE (leucine-arginine-glutamate)-dependent mechanism for adhesion of neurons to S-laminin
16. Human diabetic perineurial cell basement membrane thickening
17. Albuminuria: A marker of renal and generalized vascular disease in insulin-dependent diabetes mellitus
18. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy
19. Decreased de novo synthesis of glomerular proteoglycans in diabetes: Biochemical and autoradiographic evidence
20. 35S-Sulphate incorporations into glomerular basement membrane glycosaminoglycan is decreased in experimental diabetes
21. Alterations in the basement membrane (heparan sulfate) proteoglycan in diabetic mice
22. Reduced synthesis of basement membrane heparan sulphate proteoglycan in streptozotocin-induced diabetic mice
23. 35S-glycopeptide metabolism by diabetic glomeruli and aorta
24. Posttranscriptional effects of glucose on proteoglycan expression in mesangial cells
25. Disturbances in glomerular basement membrane glycosaminoglycans in experimental diabetes
26. Effects of streptozotocin diabetes, glucose, and insulin on the metabolism of type IV collagen and proteoglycan in murine basement membrane-forming EHS tumor tissue
27. Heparan sulphate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus
28. Effect of insulin on high glucose medium induced changes in rat glomerular epithelial cell metabolism of glycoconjugates
29. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy
30. Influence of glucose on production and N-sulfation of heparan sulfate in cultured adipocyte cells
31. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy
32. Albuminuria reflects widespread vascular damage. The Steno hypothesis
33. Pathogenesis of diabetic vascular disease: Evidence for the role of reduced heparan sulfate proteoglycan
34. Diabetic nephropathy: A clinical and pathological study based on renal biopsies
35. Glomerular proteoglycans in diabetes. Partial structural characterization and metabolism of de novo synthesized heparan-35SO4 and dermatan-35SO4 proteoglycans in streptozotocin-induced diabetic rats
36. 35SO4 proteoglycan by heparin from glomeruli of streptozotocin-induced diabetic rats
37. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells
38. Regulation of rat glomerular epithelial cell proteoglycans by high glucose medium
39. Elevated glucose decreases the content of a basement membrane associated heparan sulphate proteoglycan in proliferating cultured porcine mesangial cells
40. The KKAy mouse: A model for the rapid development of glomerular capillary basement membrane thickening
41. Altered steady-state mRNA levels of basement membrane proteins in diabetic mouse kidneys and thromboxane synthase inhibition
42. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane
43. Expression of glomerular extracellular matrix components in human diabetic nephropathy: Decrease of heparan sulfate in the glomerular basement membrane
44. Basement membrane abnormalities in human eyes with diabetic retinopathy
45. Experimental galactosemia produces a diabetic like retinopathy
46. Characterization of heparan sulfate proteoglycan from calf lens capsule and proteoglycans synthesized by cultured lens epithelial cells. Comparison with other basement membrane proteoglycans
47. Stimulation of retinal capillary pericyte protein and collagen synthesis in culture by high glucose concentrations
48. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats
49. A heparin-binding angiogenic protein- basic fibroblast growth factor - Is stored within the basement membrane
50. Altered distribution of basic fibroblast growth factor in diabetic retinopathy
51. The neuropathies of diabetes
52. Micro and macroangiopathies and other chronic degenerative complications in newly detected diabetes mellitus
53. Ultrastructure of familial amyloid polyneuropathy amyloid fibrils: Examination with high resolution electron microscopy
54. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease
55. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses
56. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome
57. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain
58. A characteristic binding affinity between heparan sulfate proteoglycans and the A4 amyloid protein of Alzheimer's disease
59. High affinity interactions between the Alzheimer's beta-amyloid precursor protein and the basement membrane form of heparan sulfate proteoglycan
60. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease
61. Perlecan binds to the beta amyloid proteins AB of Alzheimer's disease, accelerates AB fibril formation, and maintains AB fibril stability
62. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain
63. Glucose regulation and cognitive functions: Relation to Alzheimer's disease and diabetes
64. Diabetes mellitus and the risk of dementia: The Rotterdam Study
65. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study
66. Longitudinal association of vascular and Alzheimer's dementia with diabetes, and glucose tolerance
67. Distribution and origin of the basement membrane component perlecan in rat liver and primary hepatocyte culture
68. Heparan sulfate proteoglycan expression in normal human liver
69. Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. Homology to the large molecular weight molecule of basement membranes
70. Sulfate metabolism in the alloxan-diabetic rat: Relationship of altered sulfate pools to proteoglycan sulfation in heart and other tissues
71. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats
72. Delayed catabolism of apo B-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
73. Proteoglycan synthesis by bovine myocardial endothelial cells is increased by long-term exposure to high concentrations of glucose
74. Morbidity and mortality in diabetics in the Framingham population: Sixteen year follow-up study
75. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus
76. Diabetes and cardiovascular risk factors: The Framingham Study
77. Lipoprotein physiology in nondiabetic and diabetic states
78. Triglyceride-rich lipoproteins and atherosclerosis: Pathophysiological considerations
79. The mystery of diabetes and atherosclerosis: Time for a new plot
80. Plasma lipid and lipoprotein disorders in IDDM
81. The low density lipoprotein pathway and its relation to atherosclerosis
82. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E
83. Heparan sulfate proteoglycan-mediated uptake of lipoprotein E-triglyceride rich lipoprotein particles: A major pathway at physiological particle concentrations
84. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice
85. Diabetic dyslipidemia: Causes and consequences
86. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: Post-prandial metabolism and relation to premature atherosclerosis
87. Lipoprotein lipase release from BFC-1 beta adipocytes. Effects of triglyceride-rich lipoproteins and lipolysis products
88. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity
89. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta
90. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth
91. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production
92. Perlecan inhibits smooth muscle cell adhesion to fibronectin: Role of heparan sulfate
93. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone
94. Islet amyloid polypeptide in the islets of Langerhans: Friend or foe?
95. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide
96. Spontaneous diabetes mellitus in transgenic mice expression human islet amyloid polypeptide
97. Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus
98. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation
99. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
100. Islet amyloid polypeptide (amylin) modulated chylomicron metabolism in rats
101. Molecular diversity of heparan sulfate
102. Decreased activity of the heparan sulfate modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin diabetic rats
103. Diabetes mellitus induced inhibition of glucosaminyl N-deacetylase: Effect of short-term blood glucose control in diabetic rats
104. Regulation of basement membrane heparan sulfate proteoglycan, perlecan, gene expression in glomerular epithelial cells by high glucose medium
105. ECM gene expression and its modulation by insulin in diabetic rats
106. Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells
107. Lipid mediators that modulate the extracellular matrix structure and function in vascular cells
108. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins
109. Increased hyaluronan production in the glomeruli from diabetic rats: A link between glucose-induced prostaglandin production and reduced sulphated proteoglycan
110. The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells
111. Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus
112. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes
113. Cyclic AMP regulates basement membrane heparan sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells
114. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature